Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Aug 2021 · 1 min read
In brief
In brief
This study identifies aggressive liver cancer domains (ALCDs) as critical genomic regions in chemoresistant hepatoblastoma and demonstrates that the JNK1/2-p53-PARP1 pathway activates oncogenic programs in these tumors. Using patient-derived xenograft models, researchers show that the FDA-approved PARP inhibitor olaparib significantly inhibits aggressive hepatoblastoma growth, offering a potential targeted therapy for treatment-resistant cases.
Written by the GCMD Library team from the article.
Statements in this article
Hepatoblastoma is a pediatric liver cancer that ultimately requires surgery for a cure.
The most malicious form of hepatoblastoma is a chemo-resistant aggressive tumor characterized by rapid growth, metastases, and poor response to treatment.
Aggressive liver cancer domains are located on all human chromosomes, preferentially in intronic regions of oncogenes and other cancer-associated genes.
In aggressive hepatoblastoma and hepatocellular carcinoma, JNK1/2 phosphorylates p53 at Ser6.
Phosphorylated S6-p53 interacts with and delivers PARP1/Ku70 complexes to oncogenes containing aggressive liver cancer domains.
The ph-S6-p53-PARP1 complexes open chromatin around aggressive liver cancer domains and activate multiple oncogenic pathways.
Inhibition of PARP1 in patient-derived xenografts from aggressive hepatoblastoma by olaparib significantly inhibits tumor growth.
Olaparib treatment is associated with reduction of the ph-S6-p53/PARP1 complex.